Other Non-current Assets - Narrative (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
|
Sep. 30, 2026
USD ($)
payment
|
Sep. 30, 2025
USD ($)
|
Jun. 30, 2020
USD ($)
|
Sep. 30, 2026
USD ($)
payment
|
Sep. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
payment
|
|
| Intangible Asset, Finite-Lived, Acquired [Line Items] | ||||||
| Revenues | $ 7,557 | $ 12,807 | $ 35,822 | $ 31,530 | ||
| Number of guaranteed royalty payments | payment | 8 | |||||
| License agreement with Sunovion Pharmaceuticals, Inc. | ||||||
| Intangible Asset, Finite-Lived, Acquired [Line Items] | ||||||
| Minimum annual royalty receivable | $ 1,000 | $ 1,000 | $ 1,000 | |||
| Number of annual royalty payments receivable | payment | 2 | 2 | 3 | |||
| Royalty | ||||||
| Intangible Asset, Finite-Lived, Acquired [Line Items] | ||||||
| Revenues | $ 1,013 | $ 938 | ||||
| Royalty | License agreement with Sunovion Pharmaceuticals, Inc. | ||||||
| Intangible Asset, Finite-Lived, Acquired [Line Items] | ||||||
| Revenues | $ 8,000 | |||||
| X | ||||||||||
- Definition Minimum annual royalty receivable by the entity for the use of its rights and property by another party. No definition available.
|
| X | ||||||||||
- Definition Number of annual royalty payments receivable by the entity for the use of its rights and property by another party. No definition available.
|
| X | ||||||||||
- Definition Number Of Guaranteed Royalty Payments No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|